Meeting
2022 ASCO Genitourinary Cancers Symposium
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
Authors
Sophie Laramee
McMaster University, Hamilton, ON, Canada
Sophie Laramee , Sunita Ghosh , Christian K. Kollmannsberger , Aaron Richard Hansen , Lori Wood , Denis Soulieres , Christina M. Canil , Ramy Saleh , Vincent Castonguay , Georg A. Bjarnason , Naveen S. Basappa , Rodney H. Breau , Daniel Yick Chin Heng , Frederic Pouliot , Anil Kapoor , Aly-Khan A. Lalani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 304)
DOI
10.1200/JCO.2022.40.6_suppl.304
Abstract #
304
Poster Bd #
L2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman
Poster
2021 Genitourinary Cancers Symposium
Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
First Author: Jeffrey Graham
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2014 Genitourinary Cancers Symposium
Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC): What is effective? Data from the German RCC registry.
First Author: Lothar Mueller